Cargando…
Twelve per cent of 6142 eyes treated for neovascular age‐related macular degeneration (nAMD) presented with low visual outcome within 2 years. Analysis from the Swedish Macula Registry (SMR)
PURPOSE: To analyse characteristics from the SMR to explore the risk factors for visual acuity (VA) below ≤ 35 letters of the Early Treatment Diabetic Retinopathy Study (ETDRS) due to nAMD during a two‐year follow‐up. METHODS: This study evaluates 6142 treatment‐naïve eyes, with focus on a subgroup...
Autores principales: | Schroeder, Marion, Westborg, Inger, Lövestam Adrian, Monica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216980/ https://www.ncbi.nlm.nih.gov/pubmed/31517440 http://dx.doi.org/10.1111/aos.14239 |
Ejemplares similares
-
What about the fellow eye in treatment of neovascular age‐related macular degeneration? Analysis of data from the Swedish macula register
por: Lövestam Adrian, Monica, et al.
Publicado: (2022) -
New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD)
por: Patel, Prem, et al.
Publicado: (2021) -
Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)
por: Sarkar, Aira, et al.
Publicado: (2021) -
Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options
por: Tan, Colin S, et al.
Publicado: (2022) -
Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
por: Ferrante, Nicola, et al.
Publicado: (2022)